Is omega-3 good for heart patients?

The UK guideline, which says do not offer, and the trials it rests on

Is omega-3 good for heart patients, and the variant asking about fish oil, is a question the careful-claims flag answers with the UK guideline first, because it exists, it is explicit, and it is the opposite of what the shelf implies. The guideline: NICE's guidance on cardiovascular disease risk assessment and lipid modification advises clinicians not to offer omega-3 fatty acid compounds for the prevention of cardiovascular disease, in people who have not had an event and in people who have, the secondary-prevention population that heart patients belong to, a position that a GP or cardiologist in the UK follows and that a fish oil label cannot contradict. The trials it rests on: the large randomised cardiovascular outcome trials that gave around a gram a day of EPA and DHA to tens of thousands of adults, including thousands with existing heart disease, diabetes or high risk, and followed them for five to seven years, found no meaningful reduction in heart attacks, strokes or cardiovascular deaths against placebo, the earlier positive trial from the 1990s in post-heart-attack patients not being repeated in the modern trials on modern treatment, statins, blood pressure control and stents having taken the benefit a fish oil once seemed to add, the outcome-trial literature's split and the reason the guideline reads as it does. So a heart patient who takes a standard softgel to protect their heart takes it for a prevention the trials did not find and the guideline does not endorse, and the honest reason for that softgel is a different and smaller one.

The one trial that found something and the trade inside it, the standard softgel's honest place, the conversation, and the question filed

The one trial that found something is the exception the guideline's wording leaves room for: a large trial gave four grams a day of purified prescription EPA, a licensed medicine rather than a shelf product, to patients with raised triglycerides already on statins, at high cardiovascular risk, and found fewer cardiovascular events over five years, alongside the clearest atrial fibrillation signal of any omega-3 trial and more hospitalisation for it, a trade of fewer heart attacks against more rhythm problems that a cardiologist weighs for each patient against their triglycerides, their rhythm history and their other medicines, the heart problems page's two numbers, and a decision that is a prescription and never a shelf purchase, the guideline treating prescription omega-3 for raised triglycerides as a separate specialist matter. The standard softgel's honest place for a heart patient: the register's claim that EPA and DHA contribute to the maintenance of normal heart function at 250mg a day, a maintenance sentence a heart patient meets with one softgel or two fish portions a week, describing adequacy and not protection, taken by the oily-fish audit for the same reason anyone takes it and mentioned to the cardiologist because a heart patient's supplements are the cardiologist's business, the antiplatelet note sitting beside the aspirin, clopidogrel or anticoagulant most heart patients take and the atrial fibrillation signal sitting beside a rhythm history many have, both irrelevant at 250mg and both a conversation at the higher rungs. The conversation, then: a heart patient asks their cardiologist whether a standard softgel is fine, hears yes in almost every case, and does not climb to the gram-and-above rungs without them, since those rungs are where the guideline's do-not-offer and the trials' rhythm signal both live, and a patient who has heard of the four-gram trial asks whether the prescription product applies to them, which is a lipid clinic's question. The question filed: not as a treatment, the UK guideline saying do not offer omega-3 for cardiovascular prevention on the trials' null result at a gram in people with heart disease, one four-gram prescription trial finding fewer events alongside the clearest atrial fibrillation signal as a specialist's trade, and a standard softgel being the maintenance claim mentioned to the cardiologist and nothing more, with the worked example being that softgel, one at 17p, £14.99 for 90.

The verdict, not a treatment, on a guideline that says so, with a standard softgel as maintenance and a conversation

Is omega-3 good for heart patients: not as a treatment, the UK guideline advising clinicians not to offer omega-3 fatty acid compounds for cardiovascular prevention in primary or secondary prevention because the outcome trials at around a gram a day found no reduction in heart attacks, strokes or deaths in people with existing heart disease on modern treatment, with one trial of four grams of purified prescription EPA in high-risk patients on statins finding fewer events alongside the clearest atrial fibrillation signal as a cardiologist's trade, so that a heart patient's omega-3 is the register's maintenance claim at 250mg in a standard softgel, mentioned to the cardiologist beside their antiplatelet medicines and rhythm history, and nothing more without them. A standard softgel a heart patient mentions: Futuro Labs Omega 3 Fish Oil, one with food, 180mg EPA and 120mg DHA, 90 for £14.99 at 17p a day.

What to check on the label

Questions people also ask

Do doctors recommend fish oil for heart patients?

Not in the UK for prevention: NICE advises clinicians not to offer omega-3 fatty acid compounds for cardiovascular prevention in primary or secondary prevention, because the outcome trials at a gram a day found no reduction in events in people with existing heart disease, with prescription omega-3 for raised triglycerides a separate specialist decision.

Can fish oil prevent a second heart attack?

Not on the modern trials: a positive trial from the 1990s in post-heart-attack patients was not repeated in the large outcome trials on modern treatment, where statins, blood pressure control and stents had taken the benefit, so a standard softgel is the maintenance claim rather than a prevention.

What is the four-gram omega-3 heart trial?

A large trial giving four grams a day of purified prescription EPA, a licensed medicine, to patients with raised triglycerides already on statins at high cardiovascular risk, which found fewer cardiovascular events over five years alongside the clearest atrial fibrillation signal of any omega-3 trial, a trade a cardiologist weighs and a lipid clinic prescribes.

Is it safe for a heart patient to take a standard fish oil capsule?

In almost every case yes, with the cardiologist told: a 250mg softgel sits below the dose at which the atrial fibrillation signal was found and adds a negligible antiplatelet effect beside the aspirin, clopidogrel or anticoagulant most heart patients take, both being conversations only at the gram-and-above rungs.

Should a heart patient take high-dose fish oil?

Not without the cardiologist: the gram-and-above rungs are where the guideline's do-not-offer and the trials' rhythm signal both live, and a patient who has heard of the four-gram trial asks whether the prescription product applies to them, a lipid clinic's question rather than a shelf purchase.

Sources

1. NICE guidance on cardiovascular disease risk assessment and lipid modification: do not offer omega-3 fatty acid compounds for the prevention of cardiovascular disease, in primary or secondary prevention, a position based on the outcome trials at supplement doses, with prescription omega-3 for raised triglycerides a separate specialist decision. https://www.nice.org.uk/guidance/ng238
2. The large cardiovascular outcome trials of omega-3: around a gram a day of EPA and DHA in primary-prevention populations produced no meaningful reduction in major cardiovascular events, while four grams of purified EPA in people with raised triglycerides on statins reduced events in one large trial, so the supplement-dose story is maintenance and the treatment-dose story is a prescription. PubMed record
3. Meta-analyses of cardiovascular outcome trials of marine omega-3: a dose-related increase in the risk of atrial fibrillation, most evident at doses of four grams a day and small or absent below one gram, a finding that sets the honest ceiling of high-dose omega-3 for a healthy adult. PubMed record
4. EFSA Panel on Dietetic Products. Scientific opinion on the substantiation of health claims related to EPA and DHA and normal function of the heart (250mg daily condition of use). EFSA Journal 2010;8(10):1796. https://www.efsa.europa.eu/en/efsajournal/pub/1796

Related answers

• What is the best omega-3 for heart health in the UK?
• Is omega-3-acid ethyl esters good for you?
• Is Holland and Barrett omega-3 good quality?
• Is omega-3 good for gym?
• Is omega-3 good for muscles?
• Is omega-3 good for gym goers?